stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) EPS (diluted)
Alkermes plc's EPS (diluted) for fiscal 2025 was $1.43, down 34.1% from $2.17 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.01. Over the past ten years it has ranged from −$1.52 (fiscal 2015) to $2.17 (fiscal 2024); the current reading is higher than 82% of that period. Alkermes plc ranks 26th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.43 | (34.10%) |
| FY2024 | $2.17 | 3.33% |
| FY2023 | $2.10 | — |
| FY2022 | −$0.97 | — |
| FY2021 | −$0.30 | — |
| FY2020 | −$0.70 | — |
| FY2019 | −$1.25 | — |
| FY2018 | −$0.90 | — |
| FY2017 | −$1.03 | — |
| FY2016 | −$1.38 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.09 | 3,082.76% |
| Jun 2026 | $0.00 | — |
| Mar 2026 | −$0.40 | — |
| Dec 2025 | $0.29 | (40.82%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| SUPN Indivior Pharmaceuticals Inc. compare | $3.58 |
| LQDA Liquidia Corporation compare | $1.37 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc | −$0.01 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ALKS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement